annual EBIT:
$97.57M+$10.25M(+11.74%)Summary
- As of today (September 17, 2025), PCRX annual earnings before interest & taxes is $97.57 million, with the most recent change of +$10.25 million (+11.74%) on December 31, 2024.
- During the last 3 years, PCRX annual EBIT has fallen by -$35.26 million (-26.54%).
- PCRX annual EBIT is now -26.54% below its all-time high of $132.84 million, reached on December 31, 2021.
Performance
PCRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$1.92M-$10.52M(-84.58%)Summary
- As of today (September 17, 2025), PCRX quarterly earnings before interest & taxes is $1.92 million, with the most recent change of -$10.52 million (-84.58%) on June 30, 2025.
- Over the past year, PCRX quarterly EBIT has dropped by -$37.79 million (-95.17%).
- PCRX quarterly EBIT is now -95.32% below its all-time high of $41.03 million, reached on June 30, 2023.
Performance
PCRX quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$91.29M-$37.79M(-70.63%)Summary
- As of today (September 17, 2025), PCRX TTM earnings before interest & taxes is -$91.29 million, with the most recent change of -$37.79 million (-70.63%) on June 30, 2025.
- Over the past year, PCRX TTM EBIT has dropped by -$203.07 million (-181.66%).
- PCRX TTM EBIT is now -180.71% below its all-time high of $113.11 million, reached on March 31, 2024.
Performance
PCRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
PCRX EBIT Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +11.7% | -95.2% | -181.7% |
3 y3 years | -26.5% | -93.6% | -213.2% |
5 y5 years | +173.2% | +183.5% | -773.3% |
PCRX EBIT Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -26.5% | +37.6% | -95.3% | +101.4% | -180.7% | at low |
5 y | 5-year | -26.5% | +173.2% | -95.3% | +101.4% | -180.7% | at low |
alltime | all time | -26.5% | +283.1% | -95.3% | +101.4% | -180.7% | at low |
PCRX EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $1.92M(-84.6%) | -$91.29M(+70.6%) |
Mar 2025 | - | $12.44M(-57.6%) | -$53.50M(+7.7%) |
Dec 2024 | $97.57M(+11.7%) | $29.36M(-121.7%) | -$49.67M(+16.6%) |
Sep 2024 | - | -$135.01M(-440.0%) | -$42.60M(-138.1%) |
Jun 2024 | - | $39.70M(+144.0%) | $111.78M(-1.2%) |
Mar 2024 | - | $16.27M(-55.3%) | $113.11M(+43.2%) |
Dec 2023 | $87.32M(+23.1%) | $36.42M(+87.9%) | $79.01M(+131.6%) |
Sep 2023 | - | $19.38M(-52.8%) | $34.12M(+32.5%) |
Jun 2023 | - | $41.03M(-330.2%) | $25.76M(+75.3%) |
Mar 2023 | - | -$17.82M(+110.4%) | $14.70M(-69.9%) |
Dec 2022 | $70.93M(-46.6%) | -$8.47M(-176.9%) | $48.88M(-19.6%) |
Sep 2022 | - | $11.02M(-63.2%) | $60.80M(-24.6%) |
Jun 2022 | - | $29.97M(+83.2%) | $80.67M(-2.5%) |
Mar 2022 | - | $16.36M(+374.6%) | $82.72M(-3.1%) |
Dec 2021 | $132.84M(+157.9%) | $3.45M(-88.8%) | $85.40M(-15.5%) |
Sep 2021 | - | $30.90M(-3.5%) | $101.07M(+22.0%) |
Jun 2021 | - | $32.01M(+68.1%) | $82.82M(+70.7%) |
Mar 2021 | - | $19.04M(-0.4%) | $48.51M(+11.2%) |
Dec 2020 | $51.52M(+44.3%) | $19.11M(+51.0%) | $43.61M(+64.5%) |
Sep 2020 | - | $12.65M(-650.4%) | $26.52M(+95.6%) |
Jun 2020 | - | -$2.30M(-116.3%) | $13.56M(-39.6%) |
Mar 2020 | - | $14.14M(+599.3%) | $22.44M(+100.8%) |
Dec 2019 | $35.71M(+45.3%) | $2.02M(-763.0%) | $11.17M(-51.0%) |
Sep 2019 | - | -$305.00K(-104.6%) | $22.81M(-17.5%) |
Jun 2019 | - | $6.58M(+128.8%) | $27.65M(-3.5%) |
Mar 2019 | - | $2.88M(-78.9%) | $28.66M(+44.1%) |
Dec 2018 | $24.58M(-289.5%) | $13.66M(+201.7%) | $19.89M(+27.8%) |
Sep 2018 | - | $4.53M(-40.3%) | $15.57M(+89.4%) |
Jun 2018 | - | $7.59M(-228.9%) | $8.22M(-157.7%) |
Mar 2018 | - | -$5.89M(-163.1%) | -$14.25M(-44.8%) |
Dec 2017 | -$12.97M | $9.34M(-431.4%) | -$25.80M(-31.1%) |
Sep 2017 | - | -$2.82M(-81.1%) | -$37.43M(-32.3%) |
Jun 2017 | - | -$14.88M(-14.7%) | -$55.29M(+18.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2017 | - | -$17.45M(+662.6%) | -$46.74M(+48.9%) |
Dec 2016 | -$24.92M(-363.6%) | -$2.29M(-88.9%) | -$31.39M(+4.7%) |
Sep 2016 | - | -$20.68M(+227.2%) | -$29.98M(+616.5%) |
Jun 2016 | - | -$6.32M(+200.0%) | -$4.18M(-205.4%) |
Mar 2016 | - | -$2.11M(+140.3%) | $3.97M(-57.0%) |
Dec 2015 | $9.46M(-283.1%) | -$877.00K(-117.1%) | $9.23M(-48.7%) |
Sep 2015 | - | $5.12M(+179.1%) | $17.98M(+53.2%) |
Jun 2015 | - | $1.83M(-41.8%) | $11.74M(+72.8%) |
Mar 2015 | - | $3.15M(-60.0%) | $6.79M(-218.6%) |
Dec 2014 | -$5.17M(-90.3%) | $7.88M(-802.0%) | -$5.73M(-76.4%) |
Sep 2014 | - | -$1.12M(-64.0%) | -$24.23M(-32.7%) |
Jun 2014 | - | -$3.11M(-66.8%) | -$36.00M(-20.0%) |
Mar 2014 | - | -$9.37M(-11.8%) | -$45.00M(-22.0%) |
Dec 2013 | -$53.29M(+8.1%) | -$10.62M(-17.6%) | -$57.69M(-8.5%) |
Sep 2013 | - | -$12.89M(+6.4%) | -$63.07M(-3.7%) |
Jun 2013 | - | -$12.12M(-45.1%) | -$65.47M(+7.1%) |
Mar 2013 | - | -$22.06M(+37.9%) | -$61.16M(+21.2%) |
Dec 2012 | -$49.30M(+36.6%) | -$16.00M(+4.7%) | -$50.47M(+3.8%) |
Sep 2012 | - | -$15.29M(+96.0%) | -$48.63M(+15.6%) |
Jun 2012 | - | -$7.80M(-31.4%) | -$42.08M(-0.7%) |
Mar 2012 | - | -$11.38M(-19.7%) | -$42.36M(+11.2%) |
Dec 2011 | -$36.08M(+61.3%) | -$14.16M(+62.2%) | -$38.11M(+28.7%) |
Sep 2011 | - | -$8.73M(+8.0%) | -$29.60M(+6.9%) |
Jun 2011 | - | -$8.09M(+13.5%) | -$27.69M(+9.7%) |
Mar 2011 | - | -$7.12M(+25.8%) | -$25.23M(+11.0%) |
Dec 2010 | -$22.37M(-21.6%) | -$5.66M(-17.0%) | -$22.73M(-8.6%) |
Sep 2010 | - | -$6.82M(+21.2%) | -$24.88M(+2.9%) |
Jun 2010 | - | -$5.63M(+22.0%) | -$24.17M(+30.3%) |
Mar 2010 | - | -$4.62M(-40.9%) | -$18.55M(+33.1%) |
Dec 2009 | -$28.55M(-37.1%) | -$7.81M(+27.6%) | -$13.93M(+127.6%) |
Sep 2009 | - | -$6.12M | -$6.12M |
Dec 2008 | -$45.36M(+74.6%) | - | - |
Dec 2007 | -$25.99M | - | - |
FAQ
- What is Pacira BioSciences, Inc. annual earnings before interest & taxes?
- What is the all time high annual EBIT for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual EBIT year-on-year change?
- What is Pacira BioSciences, Inc. quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly EBIT year-on-year change?
- What is Pacira BioSciences, Inc. TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. TTM EBIT year-on-year change?
What is Pacira BioSciences, Inc. annual earnings before interest & taxes?
The current annual EBIT of PCRX is $97.57M
What is the all time high annual EBIT for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual earnings before interest & taxes is $132.84M
What is Pacira BioSciences, Inc. annual EBIT year-on-year change?
Over the past year, PCRX annual earnings before interest & taxes has changed by +$10.25M (+11.74%)
What is Pacira BioSciences, Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of PCRX is $1.92M
What is the all time high quarterly EBIT for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly earnings before interest & taxes is $41.03M
What is Pacira BioSciences, Inc. quarterly EBIT year-on-year change?
Over the past year, PCRX quarterly earnings before interest & taxes has changed by -$37.79M (-95.17%)
What is Pacira BioSciences, Inc. TTM earnings before interest & taxes?
The current TTM EBIT of PCRX is -$91.29M
What is the all time high TTM EBIT for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high TTM earnings before interest & taxes is $113.11M
What is Pacira BioSciences, Inc. TTM EBIT year-on-year change?
Over the past year, PCRX TTM earnings before interest & taxes has changed by -$203.07M (-181.66%)